Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | DNER | Q8NFT8 | 2/20 | 0.84 |
| ▸ | BRD2 | P25440 | 6/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | TSPO | P30536 | 1/20 | 0.81 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.77 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.77 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.77 |
| ▸ | JAK2 | O60674 | 1/20 | 0.77 |
| ▸ | BRD1 | O95696 | 1/20 | 0.77 |
| ▸ | CCL2 | P13500 | 1/20 | 0.77 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.77 |
| ▸ | EP300 | Q09472 | 1/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.77 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.77 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.77 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881274 | 1.00 | BRD4 (1.00) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL7480681 | 1.00 | BRD4 (1.00) | BRD4DNERBRD2ADORA3TSPO | |
| Hydrochloric Acid SCHEMBL15900115 | 0.99 | BRD4 (0.98) | BRD4DNERBRD2ADORA3TSPO | |
| Hydrochloric Acid SCHEMBL15900132 | 0.99 | BRD4 (0.98) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL16150161 | 0.94 | BRD4 (0.93) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL15980842 | 0.92 | BRD4 (1.00) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL19556888 | 0.92 | BRD4 (1.00) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL18017604 | 0.92 | BRD4 (1.00) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL12228129 | 0.92 | BRD4 (0.85) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL21501421 | 0.91 | BRD4 (0.84) | BRD4DNERBRD2ADORA3TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10668017-B2 | Perivascular drug delivery system | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-06-02 | — | — | US | claimed |
| US-20180042844-A1 | PERIVASCULAR DRUG DELIVERY SYSTEM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | claimed |
| EP-3268007-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | Resverlogix Corp. (CA) | 2018-01-17 | — | — | EP | claimed |
| WO-2016179222-A1 | ZNF532 FOR DIAGNOSIS AND TREATMENT OF CANCER | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-11-10 | — | — | WO | claimed |
| WO-2016147053-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | RESVERLOGIX CORP. (CA) | 2016-09-22 | — | — | WO | claimed |
| US-20250367214-A1 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4608876-A2 | ENDOCYTIC AGENTS | BioVentures, LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250262309-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS | BERG, KARA ANN | 2025-08-21 | — | — | US | disclosed |
| EP-3436006-B1 | METHODS AND COMPOSITIONS FOR MODULATING FRATAXIN EXPRESSION | WISCONSIN ALUMNI RES FOUND (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025076057-A1 | SELECTIVE INHIBITION OF MDM2-AMPLIFIED CANCERS USING TARGETED PROTEIN DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119546341-A | Proteolytic targeting chimeric (PROTAC) compositions using ubiquitin conjugated enzyme ligands | 布普格生物制药公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2011143651-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143651-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143657-A1 | MALE CONTRACEPTIVE COMPOSITIONS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143657-A1 | MALE CONTRACEPTIVE COMPOSITIONS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143660-A2 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143660-A2 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| EP-0989131-B1 | THIENOTRIAZOLODIAZEPINE COMPOUNDS AND MEDICINAL USES THEREOF | MITSUBISHI PHARMA CORP (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-0989131-A1 | THIENOTRIAZOLODIAZEPINE COMPOUNDS AND MEDICINAL USES THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262309-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS | UBE3C, UBE3A, MDM2 | BRD4 2044/4885DNER 1250/4885BRD2 991/4885 |
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | CDK9, AURKB, AURKC | BRD4 90/4885DNER 672/4885BRD2 460/4885 |
| US-20250367214-A1 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION | BRD4, BICRA, BRDT | BRD4 1/4885DNER 1293/4885BRD2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.